RE:PONTIAC Cilastatin market update? Welll I doubt that date is achievable and quite frankly this trial is not controlled by Arch.
I think Arch's current AKi trial that involves three Canadian sites should serve as a guideline and reminder to investors that obtaining the required approvals is a very lengthy approval process.
Arch is simply providing the drug and we have zero communication from either Arch or the group conducting the Pontiac trial where they are in the approval process.
I would suggest that if we are lucky they commence dosing in summer to fall of 2025 with data in 2026.
I believe this trial will be successful but later then communicated.
Cb27743 wrote:
The PONTIAC clinical team sponsoring the trial is based in Calgary and is currently preparing to submit a Clinical Trial Application (CTA) to Health Canada to proceed with the trial by the fourth quarter of 2024. Arch is acting as a study partner for grant funding opportunities, providing cilastatin drug product and providing scientific and regulatory advice.